Products for Research Use Only
RegisterLogin

Avanafil-13C5,15N, d2

CAT: 0804-HY-18252S1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18252S1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Avanafil-13C5,15N, d2 is 15N and deuterated labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis[1][2][3].
UNSPSC
12352005
Target
Endogenous Metabolite; Isotope-Labeled Compounds; NO Synthase; Phosphodiesterase (PDE)
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
COC1=C(Cl)C=C(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC([15N]4[13C@H]([13C]([2H])([2H])O)[13CH2][13CH2][13CH2]4)=N2)C=C1
Molecular Formula
C18 13C5H24D2ClN6 15NO3
Molecular Weight
491.92
References & Citations
[1]Huyut Z, et, al. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. Med Sci Monit Basic Res. 2018 Mar 13;24:47-58.|[2]Yilmaz D, et, al. The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction. Urology. 2014 Feb;83 (2) :508.e7-12. |[3]Kotera J, et, al. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012 Aug;188 (2) :668-74.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N0717S3-01L-Valine-13C5,15N, d2
HY-18252S3Avanafil-13C5
HY-14291S2Vildagliptin-13C5,15N
HY-10984S3Pomalidomide-15N,13C5
HY-18206S2Lisinopril-13C5,15N
HY-A0003S2Lenalidomide-13C5,15N
HY-B0368S1Captopril-13C5,15N
HY-B0523SAnagrelide-13C2,15N, d2
HY-Y0966S11Glycine-13C2,15N, d2
HY-B1462S2Chlorzoxazone-13C,15N, d2

Alternative Products

CatalogName
CS-O-15725Avanafil-13C5,15N
AR-A08037-01Avanafil 13C5-15N-D2
CS-O-16471Vildagliptin-13C5,15N
AR-L08119-01Lenalidomide-13C5-15N
AR-P32260-01Pralatrexate-13C5-15N
CS-BU-00128Pomalidomide-15N,13C5
TRC-V094207-5MGL-Valine-13C5,15N
TRC-P755992-10MGD-Proline-13C5,15N
OR1039772L-Proline-13C5,15N
TMIJ-0381-01L-Valine-13C5-15N

Popular Products